{
    "clinical_study": {
        "@rank": "110827", 
        "acronym": "ADAPT; T-DM1", 
        "arm_group": [
            {
                "arm_group_label": "T-DM1", 
                "arm_group_type": "Experimental", 
                "description": "single agent T-DM1 for 12 weeks (3,6 mg/kg q3w)"
            }, 
            {
                "arm_group_label": "T-DM1 + endocrine therapy", 
                "arm_group_type": "Experimental", 
                "description": "Single agent T-DM1 for 12 weeks (3,6 mg/kg q3w) with standard endocrine therapy (tamoxifen in premenopausal women and an aromatase inhibitor in postmenopausal women, if no contraindications are present, in a standard daily dosage)."
            }, 
            {
                "arm_group_label": "Trastuzumab + endocrine therapy", 
                "arm_group_type": "Active Comparator", 
                "description": "The control group will receive trastuzumab in 3-weekly schedule (8 mg/kg as loading dose and then 6 mg/kg q3w)with endocrine therapy tamoxifen in premenopausal women and an aromatase inhibitor in postmenopausal women, if not contraindications are present, in a standard daily dosage)."
            }
        ], 
        "brief_summary": {
            "textblock": "Trial to optimize neoadjuvant therapy for HER overexpression and co-expressing of hormone\n      receptors(ER and/or PR) breast cancer (HEr2+/HR+).\n\n      A new high potential trastuzumab conjugate T-DM1(trastuzumab was linked with the cytotxic\n      agent mertansine DM1)was tested with endocrine therapy and without against a standard arm\n      with trastuzumab and endocrine therapy."
        }, 
        "brief_title": "A Prospective, Randomized Multicenter, Open-label Comparison of Preoperative Trastuzumab Emtansine (T-DM1) With or Without Standard Endocrine Therapy vs. Trastuzumab With Standard Endocrine Therapy Given for Twelve Weeks in Patients With Operable HER2+/HR+ Breast Cancer Within the ADAPT Protocol.", 
        "completion_date": {
            "#text": "October 2019", 
            "@type": "Anticipated"
        }, 
        "condition": "Breast Cancer", 
        "condition_browse": {
            "mesh_term": "Breast Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "the neoadjuvant therapy Patients with HER2+/HR+ (HER2+ and ER+ and/or PR+) tumor will\n      receive single agent T-DM1 for 12 weeks (3,6 mg/kg q3w) with or without standard endocrine\n      therapy (tamoxifen in premenopausal women and an aromatase inhibitor in postmenopausal\n      women, if not contraindications are present, in a standard daily dosage). The control group\n      will receive trastuzumab in 3-weekly schedule (8 mg/kg as loading dose and then 6 mg/kg q3w)\n      in combination with the same standard endocrine therapy, if no contraindications are\n      existent."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Female patients, age at diagnosis 18 - 75 years\n\n          -  Histologically confirmed unilateral primary invasive carcinoma of the breast\n\n          -  Clinical T1 - T4 (except inflammatory breast cancer)\n\n          -  All clinical N (cN)\n\n          -  No clinical evidence for distant metastasis (M0)\n\n          -  Known HR status and HER2 status (local pathology) Tumor block available for central\n             pathology review\n\n          -  Performance Status ECOG \u2264 1 or KI \u2265 80%\n\n          -  Negative pregnancy test (urine or serum) within 7 days prior to start of inducion\n             treatment in premenopausal patients\n\n          -  Written informed consent prior to beginning specific protocol procedures, including\n             expected cooperation of the patients for the treatment and follow-up, must be\n             obtained and documented according to the local regulatory requirements\n\n          -  The patient must be accessible for treatment and follow-up\n\n        Additional Inclusion criteria for participation in the HER2+/HR+ sub-protocol:\n\n          -  Confirmed ER and/or PR positive and HER2+ by central pathology\n\n          -  Clinical cT1c - T4a-c (participation of patients with tumors >cT2 is strongly\n             recommended)\n\n          -  All clinical N (participation of patients with cN0, if cT1c is strongly recommended)\n\n          -  Patients must qualify for neoadjuvant treatment\n\n          -  LVEF > 50%; LVEF within normal limits of each institution measured by\n             echocardiography and normal ECG (within 42 days prior to induction treatment)\n\n        Exclusion Criteria:\n\n          -  Known hypersensitivity reaction to the compounds or incorporated substances\n\n          -  Prior malignancy with a disease-free survival of < 10 years, except curatively\n             treated basalioma of the skin, pTis of the cervix uteri\n\n          -  Non-operable breast cancer including inflammatory breast cancer\n\n          -  Previous or concurrent treatment with cytotoxic agents for any reason after\n             consultation with the sponsor\n\n          -  Concurrent treatment with other experimental drugs. Participation in another clinical\n             trial with any investigational not marketed drug within 30 days prior to study entry\n\n          -  Male breast cancer\n\n          -  Concurrent pregnancy; patients of childbearing potential must implement\n\n          -  a highly effective (less than 1% failure rate) non-hormonal contraceptive measures\n             during the study treatment\n\n          -  Breast feeding woman\n\n          -  Sequential breast cancer\n\n          -  Reasons indicating risk of poor compliance Patient not able to consent\n\n        Additional Exclusion Criteria for participation in the HER2+/HR+ sub-protocol:\n\n          -  Known polyneuropathy \u2265 grade 2\n\n          -  Severe and relevant co-morbidity that would interact with the application of\n             cytotoxic agents or the participation in the study\n\n          -  Inadequate organ function (e.g. hepatic impairment, pulmonary disease, etc.)\n\n          -  Uncompensated cardiac function (current unstable ventricular arrhythmia\n\n          -  requiring treatment, history of symptomatic CHF NYHA classes II-IV), history of\n             myocardial infarction or unstable angina pectoris within 6 months of enrollment,\n             history of severe hypertension, CAD - coronary artery disease)\n\n          -  Severe dyspnea\n\n          -  Pneumonitis\n\n        Abnormal blood values:\n\n          -  Thrombocytopenia > CTCAE grade 1\n\n          -  Increases in ALT/AST > CTCAE grade 1\n\n          -  Hypokalaemia > CTCAE grade 1\n\n          -  Neutropenia > CTCAE grade 1\n\n          -  Anaemia > CTCAE grade 1"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "380", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 30, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01745965", 
            "org_study_id": "WSG-AM06/ADAPT HER2+/HR+"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "T-DM1", 
                    "T-DM1 + endocrine therapy"
                ], 
                "intervention_name": "T-DM1", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Trastuzumab + endocrine therapy", 
                "intervention_name": "Trastuzumab", 
                "intervention_type": "Drug", 
                "other_name": "Herceptin"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Trastuzumab", 
                "Maytansine"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "June 13, 2013", 
        "location": [
            {
                "contact": {
                    "email": "nadia.harbeck@med-uni-muenchen.de", 
                    "last_name": "Nadia Harbeck, Prof. Dr.", 
                    "phone": "+49897095", 
                    "phone_ext": "4531"
                }, 
                "facility": {
                    "address": {
                        "city": "Munich", 
                        "country": "Germany"
                    }, 
                    "name": "Breast Center of the University of Munich (LMU)"
                }, 
                "investigator": {
                    "last_name": "Rachel W\u00fcrstlein, Dr. med.", 
                    "role": "Sub-Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "ulrike.nitz@wsg-online.com", 
                    "last_name": "Ulrike Nitz, Prof. Dr.", 
                    "phone": "+492161981", 
                    "phone_ext": "2330"
                }, 
                "facility": {
                    "address": {
                        "city": "M\u00f6nchengladbach", 
                        "country": "Germany"
                    }, 
                    "name": "Ev. Krankenhaus Bethesda Brustzentrum Niederrhien"
                }, 
                "investigator": {
                    "last_name": "Raquel von Schumann, Dr. med.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Prospective, Randomized Multicenter, Open-label Comparison of Preoperative Trastuzumab Emtansine (T-DM1) With or Without Standard Endocrine Therapy vs. Trastuzumab With Standard Endocrine Therapy Given for Twelve Weeks in Patients With Operable HER2+/HR+ Breast Cancer Within the ADAPT Protocol.", 
        "overall_contact": {
            "email": "daniel.hofmann@wsg-online.com", 
            "last_name": "Daniel Hofmann, M.Sc.", 
            "phone": "+49216156623", 
            "phone_ext": "17"
        }, 
        "overall_contact_backup": {
            "email": "sebastian.raeth@wsg-online.com", 
            "last_name": "Sebastian R\u00e4th, PhD", 
            "phone": "+49308868688", 
            "phone_ext": "13"
        }, 
        "overall_official": [
            {
                "affiliation": "Breast Center of the University of Munich (LMU), Universit\u00e4tsfrauenklinik Gro\u00dfhadern, Munich, Germany", 
                "last_name": "Nadia Harbeck, Prof. Dr.", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Ev. Krankenhaus Bethesda Brustzentrum Niederrhein, M\u00f6nchengladbach, Germany", 
                "last_name": "Ulrike Nitz, Prof. Dr.", 
                "role": "Study Chair"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Germany: Federal Institute for Drugs and Medical Devices", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "October 2019", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "pCR will be measured after 12 weeks of randomized treatment.", 
                "measure": "Comparison of the pCR rates in patients with HER2+/HR+ breast cancer  treated by preoperative T-DM1 with or without standard endocrine therapy or trastuzumab with endocrine therapy.", 
                "safety_issue": "No", 
                "time_frame": "After 12 weeks"
            }, 
            {
                "description": "Response: pCR (residual cancer burden (RCB) 0-1) or resistance/low response (RCB II-III or progressive disease)", 
                "measure": "Evaluation of dynamic testing (based on proliferation/apoptosis changes in serial biopsy and imaging by MRI) after three weeks of treatment as a surrogate parameter for response.", 
                "safety_issue": "No", 
                "time_frame": "after 3 weeks of treamtment"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01745965"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Evaluation of dynamic test regarding prediction of 5-year event-free survival (EFS)", 
                "safety_issue": "No", 
                "time_frame": "5 year after treatment"
            }, 
            {
                "measure": "Overall survival", 
                "safety_issue": "No", 
                "time_frame": "5 year after treamtment"
            }, 
            {
                "measure": "Toxicity/cardiac safety", 
                "safety_issue": "Yes", 
                "time_frame": "5 years after treatment"
            }, 
            {
                "measure": "Overall safety in the three treatment arms", 
                "safety_issue": "Yes", 
                "time_frame": "5 years after treatment"
            }, 
            {
                "measure": "Health-related quality of life (HRQL)", 
                "safety_issue": "No", 
                "time_frame": "After 5 year after treatment of last patient"
            }
        ], 
        "source": "West German Study Group", 
        "sponsors": {
            "collaborator": {
                "agency": "Roche Pharma AG", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "West German Study Group", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2013"
    }
}